Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$24.93 USD

24.93
1,205,413

-0.54 (-2.12%)

Updated May 13, 2024 04:00 PM ET

After-Market: $25.04 +0.11 (0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Edwards Lifesciences' Pipeline Strong Amid Rising Expenses

Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.

    Patterson Companies Dental Business Dull, Competition Rife

    Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.

      Align Teams Up with Exocad to Expand in Digital Scanning

      Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.

        Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius

        Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.

          Hologic's FDA Nod for Quantra Software Boosts Breast Health

          Hologic (HOLX) is consistently trying to boost its Breast Health segment.

            Here's Why You Should Add Amedisys (AMED) to Your Portfolio

            Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

              Here's Why You Should Invest in Masimo (MASI) Right Now

              Masimo (MASI) continues to grow on innovation and product launches.

                Luminex (LMNX) at 52-Week High: What's Driving the Stock?

                Luminex (LMNX) gains from recent FDA approvals and product launches.

                  Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain

                  Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.

                    AmerisourceBergen to Take Over H. D. Smith for $815 Million

                    AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.

                      Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind

                      Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.

                        Teladoc, Inc. (TDOC) Jumps: Stock Rises 10.5%

                        Teladoc, Inc. (TDOC) was a big mover last session, as the company saw its shares nearly 11/% on the day amid huge volumes.

                          Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG

                          Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.

                            DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                            DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.

                              McKesson Gains From Distribution Business Amid Pricing Woes

                              McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.

                                Haemonetics (HAE) at 52-Week High: What's Driving the Stock?

                                Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.

                                  Varian's Halcyon Receives Shonin Approval, Grows in Oncology

                                  Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.

                                    AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                    AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.

                                      Intuitive Surgical Hits a 52-Week High on Solid Prospects

                                      The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.

                                        Wright Medical (WMGI) Rides on Strong Portfolio & Innovation

                                        Wright Medical (WMGI) is focused on product innovation through research and development. However, lackluster international performance of the lower extremities segment is a matter of concern.

                                          Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

                                          Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.

                                            Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow

                                            Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.

                                              Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt

                                              Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.

                                                Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                                                Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.

                                                  Intuitive Surgical (ISRG) to Gain From Procedural Business

                                                  Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.